LANDMARK BIO
At its heart, Landmark Bio is a cell and gene therapy manufacturing company, focused on the development of innovative technologies, products and services to bridge the gap from bench to patient.
Whether you’re an academic researcher vetting therapeutic targets, a physician scientist preparing for an IND filing, or a biopharma leader advancing your pipeline product to the clinic, the right development partner can help remove obstacles, maximize efficiency, and meet milestones at an accelerated pace.
As an advanced therapy CDMO we help you achieve your ultimate clinical and commercial aspirations. Based in Watertown, Massachusetts, our founders include Harvard University, Massachusetts Institute of Technology, FUJIFILM Diosynth Biotechnologies, Cytiva, and Alexandria Real Estate Equities, Inc. Collaborating partners include Mass General Brigham, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute and Boston Children’s Hospital.
FEATURED ARTICLES
-
![landmark webinar thumb]( "From Research To Reality: Overcoming CMC Challenges In Cell & Gene Therapy")
From Research To Reality: Overcoming CMC Challenges In Cell & Gene TherapyExplore the importance of adopting a Quality by Design (QbD) approach in the development process while integrating regulatory and CMC strategies for maximum efficiency and benefit.
-
![GettyImages-1783080169-quality-management-gear-white-lab-coat-hand-digital]( "Integrating Analytical Method Development And Quality Control")
Integrating Analytical Method Development And Quality ControlAs cell and gene therapies continue to advance, a well-integrated analytical framework will be critical for accelerating development timelines and optimizing regulatory submissions.
-
![complicated path, goals to conquer-GettyImages-2175408374]( "Know Your Product, Know Your Path: A Primer On Advanced Therapy Development")
Know Your Product, Know Your Path: A Primer On Advanced Therapy DevelopmentTo prevent path-to-market setbacks, it is critical to develop a CMC strategy that proactively identifies scientific and compliance gaps, as well as mitigates risk.
-
![High speed hi-tech technology-GettyImages-2158132091]( "Getting Tech Transfer Right First Time")
Getting Tech Transfer Right First TimeBy adopting unified digital platforms, implementing standardized data models, and enabling seamless system integrations, see how established continuous digital threads can enhance connectivity.
-
![Molecule mRNA-GettyImages-1428646288]( "Optimization Of In Vitro Transcription For mRNA Production")
Optimization Of In Vitro Transcription For mRNA ProductionOptimize your mRNA production with an advanced IVT process, enhancing scalability, purity, and expression activity for clinically relevant RNA therapeutics.
-
![GettyImages-2009511436 3D illustration of small extracellular vesicles (exosomes)]( "Use Of Conventional Flow Cytometry To Study Extracellular Vesicles")
Use Of Conventional Flow Cytometry To Study Extracellular VesiclesUncover how our advanced flow cytometry method achieves precise, multiplexed characterization of extracellular vesicles, enhancing EV research and biomanufacturing processes.
-
![Lipid Nanoparticle mRNA Vaccine GettyImages-1418152448]( "RNA Nanoparticle: Formulation, Process, And Characterization")
RNA Nanoparticle: Formulation, Process, And CharacterizationAs the field grows, understanding how to formulate RNA nanoparticles effectively is essential for advancing therapeutic innovations.
CONTACT INFORMATION
Landmark Bio
300 North Beacon Street
Watertown, MA 02472
UNITED STATES
Phone: 413-206-7750
Contact: Todd Howren, SVP Business Development
LANDMARK BOB FEATURED INTERVIEW
Ran Zhang was hire number one at Landmark Bio back in 2021. Today, she's CEO of the 70+ employee cell and gene therapy manufacturer. We caught up with her and Life Science Leader chief editor Ben Comer at the JP Morgan Healthcare Conference in San Francisco for a discussion on Landmark's role in addressing the ATMP patient access and cost reduction challenges.
FEATURED SOLUTIONS
-
![GettyImages-1397843835 medical lab]( "POSTmark™ LVV")
POSTmark™ LVVAccelerate your journey from R&D to cGMP-grade LVV production with POSTmark, reaching scalable, high-quality outcomes in just 6–9 months with greater efficiency and reduced risk.
-
![GettyImages-618725044 lab, tablet, teamwork]( "POSTmark™ CAR-T")
POSTmark™ CAR-TAccelerate your path to IND readiness with POSTmark, a fully mirrored platform that streamlines R&D to cGMP scale-up in just 9–12 months while minimizing time, costs, and risks.
-
![GettyImages-2036497686-lab-team-collaboration-laboratory-tablet-computer]( "POSTmark™ AVV")
POSTmark™ AVVLeverage POSTmark to streamline your path from R&D to cGMP-scale AAV production, reducing time, costs, and risks with a fully mirrored, scalable platform.
-
![GettyImages-1181392775 lab, research]( "Future-Ready Development")
Future-Ready DevelopmentAsk us to strategize with you on your therapeutic development approach, design and execute experiments, plan, source, make and deliver your products, and help you write and review regulatory documents and interact with the agencies. We do more than a typical manufacturing organization, and we do it better.
